group and 3LL pretreated with 5×10 -8 mmol/L paclitaxel. C57BL/6 mice were divided into 3 groups: tumor -bearing group, paclitaxel-treating group and tumor-free group. 3LL cells (0.3×10 6 ) were injected via tail vein of mice. On day 8, paclitaxel (0.012 5 mg) was injected subcutaneously in the treatment group. On day 21, murine lung cells were suspended. With FACS triple staining, we analyzed expression of Treg in each group. Results The expression of TAP-1 (5.68%±0.65%), TAP-2 (89.54%
±4.8%) was remarkably higher in paclitaxel-pretreating 3LL group than that in 3LL bearing mice group with TAP-1 ( 
试剂 RPMI-1640，小牛血清为美国Gibco公司产品；
重组鼠源性GM-CSF、IL-4为Peprotech公司产品；抗鼠
两次后，含1%BSA的PBS再洗涤一次，0.5%多聚甲醛固 定，检测；本实验重复3次。 www.lungca.org www.lungca.org
